Financial Performance - The company's operating revenue for 2024 was ¥970,204,758.80, a decrease of 14.77% compared to ¥1,138,365,803.00 in 2023[25]. - The net profit attributable to shareholders for 2024 was -¥226,474,828.03, an improvement of 75.30% from -¥916,752,668.84 in 2023[25]. - The net cash flow from operating activities increased by 11.40% to ¥168,207,291.08 in 2024, compared to ¥150,992,314.83 in 2023[25]. - The total assets at the end of 2024 were ¥1,995,807,969.26, down 18.01% from ¥2,434,322,930.12 at the end of 2023[25]. - The company's total revenue for 2024 was approximately ¥970.20 million, representing a decrease of 14.77% compared to ¥1,138.37 million in 2023[63]. - The pharmaceutical research and development services and production outsourcing business accounted for 99.03% of total revenue, totaling approximately ¥960.82 million, down 14.84% from ¥1,128.32 million in the previous year[63]. - The revenue from the chemical business was approximately ¥256.19 million, a decrease of 21.71% from ¥327.24 million in 2023[63]. - The revenue from the pharmacodynamics and pharmacokinetics business was approximately ¥547.13 million, down 7.98% from ¥594.59 million in the previous year[63]. - The company reported a basic earnings per share of -¥0.45 for 2024, improving by 75.54% from -¥1.84 in 2023[25]. - The company has seen a significant reduction in net losses, indicating improved operational efficiency and financial health[25]. Strategic Initiatives - The company plans to enhance service capabilities and invest in new technology platforms to improve competitiveness and performance[7]. - The company aims to expand its market presence through high-quality services to secure more orders and improve performance[7]. - The company is committed to leveraging government support policies for long-term stable development[7]. - The company plans to strengthen its integrated CRO/CDMO platform and expand its domestic and international market presence, aiming to enhance market share[94]. - The company is focused on enhancing its quality system to comply with strict regulations in various countries, ensuring adherence to industry standards[101]. - The company is implementing a long-term employee incentive plan to stabilize and expand its core technical and management talent[97]. - The company is committed to continuous investment in technology R&D to mitigate risks associated with new technology development failures[100]. - The company is in the process of developing a comprehensive R&D service platform for nucleic acid drugs, which is expected to enhance its capabilities in innovative drug development[73]. Market Trends - The CRO/CDMO industry is expected to see a long-term demand increase due to the growing focus on innovative drug development and production services[34]. - Global biopharmaceutical investment is projected to rebound from $71 billion in 2023 to $102 billion in 2024, a year-on-year increase of 43.7%[35]. - The company aims to empower pharmaceutical innovation and enhance life health through its mission and vision[36]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[171]. - The company plans to enter the European market in 2024, with projected revenues of $100 million in the first year[171]. Risk Management - The company faces risks including declining service demand, loss of core technology and management personnel, and insufficient working capital for expansion[9]. - The company emphasizes proactive research on policies and market trends to mitigate risks from regulatory changes[7]. - The company recognizes the risk of currency fluctuations affecting its performance, as revenues are primarily sourced from overseas clients and settled in USD or EUR[101]. - The company faces risks related to a potential decline in demand for pharmaceutical R&D services, which could significantly impact business if industry growth trends change[99]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholders' rights[107]. - The board of directors consists of 6 members, including 3 independent directors, meeting legal and regulatory requirements[110]. - The company is committed to transparent information disclosure, ensuring all shareholders have equal access to information[114]. - The company has implemented a performance evaluation and incentive mechanism to enhance management efficiency and align compensation with company performance[113]. - The company has been subject to regulatory scrutiny due to non-compliance with goodwill and long-term asset impairment regulations, as well as deficiencies in internal control systems[136]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[168]. - The company adheres to multiple environmental regulations, including the Environmental Impact Assessment Law and the Environmental Protection Law, with implementation dates ranging from 2003 to 2023[168]. - The company has established a comprehensive set of environmental protection standards, including those for hazardous waste management and air quality[168]. - The company has a comprehensive waste management strategy that includes regular monitoring and reporting of waste discharge levels[173]. - The company is committed to reducing its environmental impact through effective waste management practices and compliance with emission standards[173]. Employee Management - The company has a workforce of nearly 2,000 employees in its pharmaceutical research and development services, with over 30% holding master's degrees or higher[59]. - The company has established a compensation management system that includes fixed salaries, allowances, project bonuses, annual performance bonuses, and long-term incentives[151]. - The company is committed to enhancing employee training, with a focus on both online and offline training methods to improve skills and efficiency[152]. - The company has implemented a performance-oriented compensation philosophy to attract and retain top talent[151]. Shareholder Engagement - The company held its first temporary shareholders' meeting on January 10, 2024, with an investor participation rate of 20.78%[118]. - The annual shareholders' meeting took place on May 31, 2024, with a participation rate of 35.05%[118]. - The company has ensured that minority shareholders have ample opportunities to express their opinions and that their legal rights are fully protected[155]. Financial Adjustments - The company received a warning letter from the China Securities Regulatory Commission regarding non-compliance in goodwill impairment testing and inaccuracies in long-term asset impairment[197]. - The company corrected the goodwill amount on the balance sheet as of June 30, 2024, from ¥164,030,380.19 to ¥139,260,380.19, a reduction of ¥24,770,000.00[198]. - The retained earnings were adjusted from -¥492,233,377.89 to -¥517,003,377.89 as of June 30, 2024, reflecting the impact of the correction[198].

Financial Performance - The company's revenue for Q1 2025 was ¥261,261,312.24, representing an increase of 11.37% compared to ¥234,594,741.64 in the same period last year[5] - Net profit attributable to shareholders was ¥6,642,081.65, a significant turnaround from a loss of ¥25,460,550.66 in the previous year, marking a 126.09% improvement[5] - Basic and diluted earnings per share improved to ¥0.01 from a loss of ¥0.05, reflecting a 120.00% increase[5] - Operating profit for the current period was ¥9,366,855.16, a significant recovery from a loss of ¥27,268,564.97 in the previous period[19] - Net profit attributable to the parent company was ¥6,642,081.65, compared to a loss of ¥25,460,550.66 in the previous period, marking a turnaround[20] Cash Flow and Investments - The net cash flow from operating activities decreased by 60.14%, down to ¥10,058,746.76 from ¥25,233,688.30 year-on-year[5] - The company reported a net cash outflow from investing activities of ¥11,349,624.10, an improvement from a net outflow of ¥32,705,291.85 in the previous period[23] - The cash and cash equivalents at the end of the period were ¥343,000,036.81, compared to ¥326,002,953.77 at the end of the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,987,063,157.81, a slight decrease of 0.44% from ¥1,995,807,969.26 at the end of the previous year[5] - Current assets totaled CNY 645,941,574.54, showing a marginal increase from CNY 644,069,184.30[16] - Total liabilities decreased to CNY 742,649,696.89 from CNY 757,745,151.71, reflecting a reduction of about 2%[17] - Non-current liabilities totaled CNY 408,903,156.39, a decrease from CNY 411,047,175.16, indicating a reduction of about 0.3%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,012[11] - The company plans to issue shares to specific targets, pending approval from shareholders and regulatory bodies[14] Operational Efficiency - Total operating costs decreased to ¥260,328,377.29 from ¥263,463,408.41, a decline of 1.6%[19] - Research and development expenses decreased to ¥12,101,507.40 from ¥16,901,112.25, reflecting a 28.5% reduction[19] Other Financial Metrics - The weighted average return on equity increased to 0.55% from -1.79% in the previous year, showing a positive trend[5] - Financial expenses decreased by 50.21%, down to ¥1,121,555.27 from ¥2,252,352.80, primarily due to reduced interest expenses[10] - The company recorded a non-operating income of ¥8,213,051.55, which includes gains from the disposal of non-current assets[7] - The company experienced a foreign exchange loss of ¥272,754.98 in other comprehensive income, contrasting with a gain of ¥1,875,939.70 in the previous period[20] - The company's cash and cash equivalents decreased to CNY 347,919,860.57 from CNY 368,328,773.14[16] - Accounts receivable rose to CNY 202,796,534.68, up from CNY 176,719,261.33, indicating a growth of approximately 14.7%[16] - Inventory increased to CNY 13,596,368.84 from CNY 11,441,020.50, representing a growth of approximately 18.9%[16] - The company reported a net loss of CNY 673,929,631.53 in retained earnings, slightly improved from a loss of CNY 680,571,713.18[18] - The company's equity attributable to shareholders increased to CNY 1,220,230,623.22 from CNY 1,213,861,296.55[18]

睿智医药（300149）公告，2025年第一季度营业收入2.61亿元，同比增长11.37%。净利润664.21万元， 同比增长126.09%。 ...

Group 1 - The core business of the company is to provide drug discovery, development, and production services for global pharmaceutical companies, biotechnology firms, and research institutions [1] - The CRO/CDMO segment is the company's core business, consisting of four service modules: chemical CRO, biological CRO, small molecule CDMO, and large molecule CDMO [1] - The company is one of the few domestic leaders with full-process service capabilities in preclinical CRO and CMO, ranking among the top three in the preclinical CRO market in China [1] Group 2 - As of the latest quarterly report for Q3 2024, the company achieved a revenue of 719 million yuan, a year-on-year decrease of 15.09% [1] - The net profit for the same period was -61.67 million yuan, reflecting a year-on-year decline of 96.88% [1] - The company's gross profit margin stands at 19.22% [1] Group 3 - The company's latest market performance shows a closing price of 5.88 yuan, an increase of 1.91%, with a current price-to-book ratio of 2.14 and a total market capitalization of 2.928 billion yuan [1] - A total of 31 institutions hold shares in the company, with a combined holding of 2.0099 million shares valued at 13 million yuan [1]

北京博星证券投资顾问有限公司 关于睿智医药科技股份有限公司 详式权益变动报告书 之 财务顾问核查意见 财务顾问 二〇二五年四月 上市公司名称： 睿智医药科技股份有限公司 上市地点： 深圳证券交易所 股票简称： 睿智医药 股票代码： 300149 | 第一节 释义 | | --- | | 第二节 序言 | | 第三节 财务顾问承诺与声明 | | 一、财务顾问承诺 . | | 二、财务顾问声明 | | 第四节 财务顾问意见… | | 一、对本次详式权益变动报告书内容的核查…………………………………………………………………………………………… 7 | | 二、对信息披露义务人权益变动目的的核查 ………………………………………………… 7 | | 三、对信息披露义务人及其一致行动人的核查 7 | | 四、对信息披露义务人进行证券市场规范化运作辅导的情况 13 | | 五、信息披露义务人的股权控制结构与其控股股东、实际控制人支配信息披 | | 露义务人的方式 | | 六、对信息披露义务人本次增持资金来源及合法性的核查 16 | | 七、对信息披露义务人本次收购所履行的决策程序的核查 17 | | 八、对信息披露义务人收 ...

中国经济网北京4月2日讯睿智医药（300149）(300149.SZ)昨晚发布2024年度向特定对象发行股票预案 (修订稿)。本次向特定对象发行股票预计募集资金总额不超过31,630.38万元(含本数)，扣除发行费用后 的募集资金净额将全部用于补充流动资金、偿还银行借款。 本次向特定对象发行股票的发行对象为睿联投资，发行对象已与公司签署了《附条件生效的股份认购协 议(修订稿)》，拟以现金方式认购本次发行的股票。截至预案公告时，睿联投资的实际控制人WOO SWEE LIAN为上市公司董事长、首席执行官(CEO)，其合计控制上市公司5%以上股份，且WOOSWEE LIAN在完成广东省江门市中级人民法院出具的第(2024)粤07民初66号《民事调解书》强制执行过户 后，将成为公司的控股股东和实际控制人；本次发行后睿联投资将成为公司的控股股东，WOO SWEE LIAN仍为公司实际控制人。根据《上市规则》的规定，本次向特定对象发行股份构成关联交易。 本次向特定对象发行股票的定价基准日为公司第六届董事会第五次会议决议公告日。本次向特定对象发 行股票的发行价格为5.27元/股，不低于定价基准日前20个交易日公司股票交易均 ...

睿智医药科技股份有限公司（以下简称"公司"）拟向特定对象发行股票， 募集资金不超过 31,630.38 万元（以下简称"本次发行"）。根据《国务院办公厅 关于进一步加强资本市场中小投资者合法权益保护工作的意见》（国办发 2013110 号）《国务院关于加强监管防范风险推动资本市场高质量发展的若干意 见》（国发202410 号）和《关于首发及再融资、重大资产重组摊薄即期回报有 关事项的指导意见》（证监会公告201531 号）等法律、法规、规章及规范性文 件的要求，为维护中小投资者利益，公司就本次发行对即期回报摊薄的影响进行 了认真、审慎、客观的分析，并提出了具体的填补回报措施，且相关主体对公司 填补回报措施能够得到切实履行做出了承诺。具体情况如下： 证券代码：300149 证券简称：睿智医药 公告编号：2025-15 睿智医药科技股份有限公司 关于 2024 年度向特定对象发行股票摊薄即期回报的影响与填补回报 措施及相关主体承诺（修订稿）的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本次发行摊薄即期回报对公司主要财务指标的影响 （一）本次发行摊薄即期回报 ...

Group 1 - The core viewpoint of the article is that Ruizhi Pharmaceutical is planning a private placement of shares to enhance its capital strength and seize opportunities in the CRO/CDMO industry, which is expected to continue growing due to increasing demand for drug development and production services [1][6][19] Group 2 - The background of the issuance is that the company operates in the CRO/CDMO industry, providing drug discovery, development, and production services to global pharmaceutical companies and research institutions [1][2] - The demand for CRO/CDMO services remains strong due to the increasing focus on innovative drug development and the need for cost-effective solutions in the pharmaceutical industry [2][3] - The industry is characterized by a continuous need for outsourcing drug research and production, driven by advancements in technology and the emergence of new drug targets [2][3][4] Group 3 - The company aims to raise up to 316.30 million RMB through this issuance, which will be used to supplement working capital and repay bank loans, thereby optimizing its financial structure and enhancing its competitive edge [6][19] - The issuance will involve the issuance of domestic ordinary shares (A shares) at a price of 5.27 RMB per share, which is not lower than 80% of the average trading price over the previous 20 trading days [8][9] Group 4 - The issuance is deemed necessary and reasonable as it aligns with the company's strategic goals and will enhance its ability to respond to market opportunities [19][24] - The company has committed to measures to mitigate the potential dilution of immediate returns for shareholders resulting from the issuance [19][20][23]

Core Viewpoint - The agreement outlines the terms for the issuance of shares by Ruizhi Medical Technology Co., Ltd. to Jiangmen Ruilian Medical Investment Co., Ltd. for the year 2024, including share transfer and ownership changes [1][2][3]. Group 1: Share Issuance Agreement - The agreement was signed on April 1, 2025, between Ruizhi Medical Technology Co., Ltd. and Jiangmen Ruilian Medical Investment Co., Ltd. [1] - The total registered capital of Ruizhi Medical is RMB 497.96 million, with a total share count of 100% held by MEDICAL LIMITED [1]. - WOO SWEE LIAN, the actual controller, currently holds 5.11% of the shares, with an additional 4.56% held by MEGA STAR [1]. Group 2: Share Transfer and Ownership Changes - Following a court ruling, WOO SWEE LIAN and his associates will hold 15.70% of the shares after the forced transfer of 30,033,098 shares from another shareholder [2]. - After the completion of a share transfer agreement, WOO SWEE LIAN and his associates will collectively own 21.18% of the shares, maintaining his position as the controlling shareholder [3]. Group 3: Subscription Details - The agreement allows for the issuance of up to 60,019,704 shares, representing 30% of the total share capital prior to the issuance, at a price of RMB 5.27 per share [4][5]. - The subscription amount will be determined by the number of shares multiplied by the issuance price, with funds sourced legally by the subscriber [5]. - The shares subscribed will have a lock-up period of 18 months post-issuance [5]. Group 4: Legal and Compliance - The agreement is subject to approval from the board of directors and shareholders, as well as regulatory approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission [7]. - Any modifications to the agreement must be documented in writing and comply with legal procedures [7][8].

证券代码：300149 证券简称：睿智医药 睿智医药科技股份有限公司（以下简称"公司"或"睿智医药"）为进一步 提升公司核心竞争力及持续经营能力，拟向特定对象发行股票（以下简称"本次 向特定对象发行股票"或"本次发行"）。根据《上市公司证券发行注册管理办 法》的规定，公司就本次向特定对象发行股票募集资金运用的可行性说明如下： 一、本次募集资金使用计划 本次向特定对象发行股票募集资金总额不超过 31,630.38 万元，扣除发行费 用后的募集资金净额将全部用于补充流动资金、偿还银行借款。 1、把握医药行业发展机遇，增强公司市场竞争力 睿智医药科技股份有限公司 2024年度向特定对象发行股票 募集资金使用的可行性分析报告 （修订稿） 二〇二五年四月 二、本次募集资金的必要性和可行性分析 （一）本次募集资金的必要性 受益于全球医药行业刚需属性的大环境，医药行业未来仍将保持持续增长态 势，根据 Frost&Sullivan 统计，2022 年全球医药市场总额达到 14,950 亿美元， 2018—2022 年的复合增速为 4.2%，预计 2027 年将达到 19,016 亿美元，2022— 2027 年的复合增速为 ...